Moreover, the impressive intracranial objective response rate (iORR) of 71% in the Phase 2 study indicates that the Bria-IMT + CPI regimen could provide meaningful benefits to a significant ...
According to study findings published in JAMA Oncology, after a median follow-up of 13.6 months, the intracranial overall response rate (iORR; percentage of patients with brain tumors who respond to ...